Regeneron Pharmaceuticals, Inc.

REGN

NASDAQ

542.03

USD

-7.97(-1.45%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Regeneron Pharmaceuticals, Inc. fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

13.77

Price/Book

1.97

Debt/Equity

9.20%

Return on Equity

14.77%

Dividend Yield

0.32%

EBITDA

5.32B

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	8,497,100,000	16,071,700,000	12,172,900,000	13,117,200,000	14,202,000,000
Gross Profit	7,377,200,000	13,634,200,000	10,612,500,000	11,301,400,000	12,231,500,000
Operating Income	3,576,600,000	8,946,800,000	4,738,900,000	4,047,100,000	3,990,700,000
Net Income	3,513,200,000	8,075,300,000	4,338,400,000	3,953,600,000	4,412,600,000
Total Assets	17,163,300,000	25,434,800,000	29,214,500,000	33,080,200,000	37,759,400,000
Total Current Liabilities	2,806,800,000	3,451,000,000	3,849,100,000	3,423,400,000	3,944,300,000
Total Equity	11,025,300,000	18,768,800,000	22,664,000,000	25,973,100,000	29,353,600,000
Free Cash Flow	2,003,500,000	6,529,400,000	4,424,800,000	3,667,600,000	3,664,600,000
Cash from Operations	2,618,100,000	7,081,300,000	5,014,900,000	4,594,000,000	4,420,500,000
Cash from Investing	-70,600,000	-5,384,700,000	-3,784,600,000	-3,185,100,000	-2,468,100,000
Cash from Financing	-1,970,500,000	-1,005,800,000	-1,009,000,000	-1,790,100,000	-2,200,500,000
Net Change in Cash	577,000,000	690,800,000	221,300,000	-381,600,000	-248,800,000